 |
2011
A multicenter phase II trial of neoadjuvant letrozole plus low dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG07): the efficacy and its correlation with circulating endothelial cells. |
| Takayuki Ueno, Norikazu Masuda, Shunji Kamigaki, Takashi Morimoto, Seigo Nakamura, Katsumasa Kuroi, Hiroji Iwata, Shinji Ohno, Sunao Tanaka, Masakazu Toi |
| 2011 American Society of Clinical Oncology, Chicago (USA), Jun. 2011 |
2010
Update HER2 Therapy for Breast Cancer |
| Dr. Jose Baselga, M.D., Ph.D. |
| 33rd San Antonio Breast Cancer Symposium, Meet the Experts, San Antonio(USA), Dec.2010 |
Indication of adjuvant chest wall irradiation after mastectomy in Japan from the standpoint of the international collaborative study SUPREMO |
| Kuroi K, Masuda N, Aogi K, Iwata H, Ueno T, Ohno S, Kashiwaba M, Sato N, Nakamura S, Nakayama T, Toi M; Japan Breast Cancer Research Group (JBCRG) |
| The 18th Annual Meeting of the Japanese Breast Cancer Society, Sapporo, Jun 2010 |
The contrivance of success in the clinical trial and the prospect in the future on JBCRG |
| Masuda N, Aogi K, Iwata H, Ueno T, Ohno S, Kashiwaba M, Kuroi K, Sato N, Nakamura S, Nakayama T, Toi M; Japan Breast Cancer Research Group (JBCRG) |
| The 18th Annual Meeting of the Japanese Breast Cancer Society, Sapporo, Jun 2010 |
A multicenter, randomized phase II study of neoadjuvant chemotherapy including trastuzumab with cyclophosphamide with docetaxel in patients with operable HER2-positive breast cancer (JBCRG-10 study). |
| N. Masuda, M. Toi, T.Ueno, K. Aogi, H. Iwata, S. Ohno, K. Kuroi, N. Sato, S. Nakamura; Japan Breast Cancer Research Group (JBCRG) |
| 2010 American Society of Clinical Oncology, Chicago (USA), Jun. 2010 |
2009
Comparison of Molecular characterization of ER+early-stage cancer by standardized quantitative RT-PCR analysis between Japanese and North American populations. |
| Masuda N, Yamanaka T, Iwata H, Ohno S, Nakamura S, Kashiwaba M, Kamigaki S, Aogi K, Ueno T, Toi M; Japan Breast Cancer Research Group (JBCRG) |
| ASCO Breast, San Francisco, USA, Oct. 2009 |
View of new clinical trials for breast cancer patients considered from the results of preoperative systemic therapy on JBCRG |
| Masuda N, Aogi K, Iwata H, Ueno T, Ohno S, Kashiwaba M, Kuroi K, Sato N, Nakamura S, Nakayama T, Toi M; Japan Breast Cancer Research Group (JBCRG) |
| The 47th Annual Meeting of Japan Society of Clinical Oncology (Yokohama) Symposium16, 2009 |
Phase I/II study of irinotecan hydrochloride (CPT-11) combined with S-1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG-M01 study) |
| Saji S, Ishiguro H, Iwata H, Nakamura S, Kuroi K, Ohno S, Masuda N, Yamanaka T, Sasaki Y, Inamoto S, Toi M; Japan Breast Cancer Research Group (JBCRG) |
| The 17th Annual Meeting of the Japanese Breast Cancer Society, Tokyo, Jul 2009 |
Correlation between docetaxel-induced skin toxicity and the use of steroids and H2 blockers: A multi-institution survey |
| K. Kawaguchi, H. Ishiguro, S. Morita, S. Nakamura, S. Ohno, N. Masuda, H. Iwata, K. Aogi, K. Kuroi, M. Toi; Japan Breast Cancer Research Group (JBCRG) |
| 2009 American Society of Clinical Oncology, New Orleans (USA), Jun. 2009 |
The first report of the association between the recurrence score and risk of recurrence in Japanese population (JBCRG-TR03) |
| Toi M, Iwata H, Masuda N, Ohno S, Nakamura S, Yamanaka T, Nakayama T,Kashiwaba M, Kamigaki S, Aogi K, Ueno T, Kuroi K: Japan Breast Cancer Research Group (JBCRG) |
| Kyoto Breast Cancer Consensus Conference International Convention 2009, Kyoto, April 2009 |
2008
Significance of HER2/TOPO IIα analysis as a predictive factor of the therapeutic effect in preoperative chemotherapy (JBCRG-TR01) |
| Shinichiro Horiguchi, Katsumasa Kuroi, Masato Takahashi, Keiko Yamashita, Nobuaki Sato, Hiroji Iwata, Norikazu Masuda, Seigo Nakamura, Masakazu Toi; Japan Breast Cancer Research Group (JBCRG) |
| The 16th Annual Meeting of the Japanese Breast Cancer Society, Osaka, Sep 2008 |
JBCRG03: Preoperative chemotherapy using Docetaxel 75 followed by FEC 100 as primary systemic chemotherapy for operable breast cancer |
| Naohito Yamamoto, Hiroji Iwata, Nobuaki Sato, Norikazu Masuda, Seigo Nakamura, Katsumasa Kuroi, Masafumi Kurosumi, Hitoshi Tsuda, Futoshi Akiyama, Masakazu Toi; Japan Breast Cancer Research Group (JBCRG) |
| The 16th annual meeting of the Japanese Breast Cancer Society, Symposium 2 ,Osaka, Sep. 2008 |
New system to promote translational researches using samples of clinical trials |
| Akemi Kataoka, Shinji Ohno, Masakazu Toi, Seigo Nakamura, Katsumasa Kuroi, Hiroji Iwata, Tatsuya Toyama, Norikazu Masuda, Eriko Tokunaga, Kazumi Horiguchi; Japan Breast Cancer Research Group (JBCRG) |
| The 108th Annual Congress of Japan Surgical Society, Nagasaki, May 2008 |
Neoadjuvant docetaxel (DOC 75) followed by fluorouracil, epirubicin, cyclophosphamide (FEC 100) in primary operable breast cancer: Results of a multicenter phase II trial: JBCRG03 trial |
| Sato N, Iwata H, Masuda N, Nakamura S, Yamamoto N, Kuroi K, Kurosumi M, Tsuda H, Akiyama F, Toi M; Japan Breast Cancer Research Group (JBCRG) |
| 6th European Breast Cancer Conference, Poster, Berlin (Germany), Apr. 2008 |
2007
JBCRG03:Preoperative chemotherapy using Docetaxel, followed by FEC 100 - Review of and breakthrough by JBCRG01 and 02 - |
| Masahiro Kashiwaba, Go Wakabayashi, Seigo Nakamura, Katsumasa Kuroi, Hiroji Iwata, Shinji Ohno, Norikazu Masuda, Nobuaki Sato, Taro Asaga, Naohito Yamamoto, Kenjiro Aogi, Yasuyuki Sato, Masafumi Kurosumi, Hitoshi Tsuda, Futoshi Akiyama, Masakazu Toi; Japan Breast Cancer Research Group (JBCRG) |
| The 15th annual meeting of the Japanese Breast Cancer Society, Presidential Symposium 2 , Yokohama, June 2007 |
Network construction to promote translational researches |
| Akemi Kataoka, Shinji Ohno, Masakazu Toi, Seigo Nakamura, Katsumasa Kuroi, Hiroji Iwata, Tatsuya Toyama, Norikazu Masuda, Eriko Tokunaga; Japan Breast Cancer Research Group (JBCRG) |
| The 15th annual meeting of the Japanese Breast Cancer Society, Yokohama, June 2007 |
JBCRG02: Study of FEC 100 followed by docetaxel 100 as preoperative chemotherapy in primary breast cancer |
| Tsuyoshi Hamaoka, Seigo Nakamura, Norikazu Masuda, Hiroji Iwata, Katsumasa Kuroi, Masafumi Kurosumi, Hitoshi Tsuda, Futoshi Akiyama, Masakazu Toi; Japan Breast Cancer Research Group (JBCRG) |
| The 15th annual meeting of the Japanese Breast Cancer Society, Yokohama, June 2007 |
2006
Significance of HER2 for predicting pathological complete response to preoperative treatment with FEC followed by docetaxel |
| Toi M, Nakamura S, Takatsuka Y, Kuroi K, Iwata H, Ohno S, Masuda N, Tsuda H, Kurosumi M, Akiyama F；Japan Breast Cancer Research Group (JBCRG). |
| 29th San Antonio Breast Cancer Symposium, Poster, San Antonio (USA), Dec. 2006 |
Premature ovarian disfunction induced by neopadjuvant chemotherapy (FEC followed by docetaxel) for breast cancer |
| Shinano Hitomi, Hamaoka Tsuyoshi, Nakamura Seigo, Toi Masakazu, Kuroi Katsumasa; Japan Breast Cancer Research Group (JBCRG). |
| 3rd Organisation for Oncology and Translational Research, Hong Kong, Oral, Sep. 2006 |
Study of FEC followed by docetaxel 100 as preoperative chemotherapy in primary breast cancer - JBCRG02 - |
| Seigo Nakamura, Norikazu Masuda, Hiroji Iwata, Masakazu Toi, Katsumasa Kuroi, Futoshi Akiyama; Japan Breast Cancer Research Group (JBCRG) |
| The 14th annual meeting of the Japanese Breast Cancer Society, Kanazawa, July 2006 |
Preoperative chemotherapy in primary breast cancer: How to define pCR: Our Challenge. |
| Katsumasa Kuroi, Seigo Nakamura, Masakazu Toi, Hiroji Iwata, Mikihiro Kusama, Norikazu Masuda, Eisei Shin, Shinji Ohno, Kosuke Yamazaki, Yuichi Takatsuka, Kazufumi Hisamatsu, Masahiro Kashiwaba, Yasuyuki Sato, Hiroshi Kaise, Futoshi Akiyama, Hitoshi Tsuda, Masafumi Kurosumi; Japan Breast Cancer Research Group (JBCRG) |
| The 106th Annual Congress of Japan Surgical Society, Tokyo, March 2006 |
The effect of pathological response of multicenter phase II trial of fluorouracil, epirubicin, cyclophosphamide (FEC 100) followed by docetaxel (DOC 75) in primary operable breast cancer. |
| Nakamura S, Toi M, Takatsuka Y, Kuroi K, Iwata H, Ohno S, Masuda N, Tsuda H, Kurosumi M, Akiyama F; Japan Breast Cancer Research Group (JBCRG) |
| 5th European Breast Cancer Conference, Nice (France), Mar. 2006 |
2005
Feasibility and efficacy of phase II trial of sequential preoperative FEC 100 followed by Docetaxel 100 in primary operable breast cancer. |
| Nakamura S, Masuda N, Iwata H, Toi M, Kuroi K, Akiyama F; Japan Breast Cancer Research Group (JBCRG) |
| 2nd Organisation for Oncology and Translational Research, Tokyo, Nov. 2005 |
Results of survey conducted on perioperative chemotherapy and supportive care in primary breast cancer |
| Norikazu Masuda, Seigo Nakamura, Masakazu Toi, Hiroji Iwata, Shinji Ohno, Yuichi Takatsuka, Kazufumi Hisamatsu, Kosuke Yamazaki, Mikihiro Kusama, Hiroshi Kaise, Yasuyuki Sato, Masahiro Kashiwaba, Eisei Shin, Katsumasa Kuroi, Futoshi Akiyama, Hitoshi Tsuda, Masafumi Kurosumi; Japan Breast Cancer Research Group(JBCRG) |
| The 13th annual meeting of the Japanese Breast Cancer Society, Kurashiki, June 2005 |
2004
The effect of Pathological Response of Multicenter phase II trial of sequential FEC followed by docetaxel in primary operable breast cancer – interim analysis - |
| Ohno S, Toi M, Kuroi K, Nakamura S, Iwata H, Kusama M, Masuda N, Yamazaki K, Hisamatsu K, Sato Y, Takatsuka Y, Akiyama F; Japan Breast Cancer Research Group (JBCRG). |
| 27th San Antonio Breast Cancer Symposium, Poster, SanAntonio (USA), Dec. 2004 |
Multiphase II trial of sequential FEC followed by docetaxel in primary operative breast cancer. |
| Ohno S, Toi M, Kuroi K, Nakamura S, Iwata H, Kusama M, Masuda N, Yamazaki K, Hisamatsu K, Sato Y, Takatsuka Y, Kurozumi M, Tsuda H, Akiyama F; Japan Breast Cancer Research Group (JBCRG). |
| 1st Organisation for Oncology and Translational Research, Hong Kong, Oct. 2004 |
Unargued issues on the pathological assessment of response in primary sytemic therapy for breast cancer. |
| Kuroi K, Toi M, Takatsuka Y, Akiyama F, Tsuda H, Kurosumi M; Japan Breast Cancer Research Group (JBCRG). |
| 1st Organisation for Oncology and Translational Research, Hong Kong, Oct. 2004 |
Review of the study of CEF followed by Docetaxel as preoperative chemotherapy in primary breast cancer |
| Hiroji Iwata, Seigo Nakamura, Masakazu Toi, Eisei Shin, Norikazu Masuda, Shinji Ohno, Yuichi Takatsuka, Kazufumi Hisamatsu, Kosuke Yamazaki, Mikihiro Kusama, Hiroshi Kaise, Yasuyuki Sato, Katsumasa Kuroi, Futoshi Akiyama, Hitoshi Tsuda, Masafumi Kurosumi; Japan Breast Cancer Research Group (JBCRG) |
| The 12th annual meeting of the Japanese Breast Cancer Society, Kokura, June 2004 |
Cyclophosphamide, epirubicin, and fluorouracil followed by docetaxel (CEF - DOC) as preoperative chemotherapy in primary operable breast cancer. |
| Nakamura S, Ohno S, Toi M, Takatsuka Y, Kuroi K, Iwata H, Hisamatsu K, Yamazaki K, Masuda N, Akiyama F; Japan Breast Cancer Research Group (JBCRG) |
| 2004 American Society of Clinical Oncology, New Orleans (USA), Jun. 2004 |
Cyclophosphamide, epirubicin, and fluorouracil followed by docetaxel (CEF - DOC) as preoperative chemotherapy in primary operable breast cancer. |
| Kuroi K, Toi M, Takatsuka Y, Iwata H, Ohno S, Kusama M, Shin E, Hisamatsu K, Yamazaki K, Sato Y, Masuda N, Kaise H, Akiyama F, Nakamura S; Japan Breast Cancer Research Group (JBCRG) |
| 15th International Congress on Anti Cancer Treatment, Paris (France), Feb. 2004 |
2003
Review of the study of CEF followed by Docetaxel as preoperative chemotherapy in primary breast cancer |
| Eisei Shin, Seigo Nakamura, Masakazu Toi, Yuichi Takatsuka, Yasuyuki Sato, Shinji Ohno, Hiroji Iwata, Mikihiro Kusama, Kazufumi Hisamatsu, Hiroshi Kaise, Kosuke Yamazaki, Katsumasa Kuroi, Futoshi Akiyama; Japan Breast Cancer Research Group (JBCRG) |
| The 41th annual meeting of the Japan Society of Clinical Oncology, Sapporo, Oct. 2003 |
Review of the study of CEF followed by Docetaxel as preoperative chemotherapy in primary breast cancer |
| Katsumasa Kuroi, Masakazu Toi, Yuichi Takatsuka, Shinji Ohno, Hiroji Iwata, Mikihiro Kusama, Eisei Shin, Yasuyuki Sato, Kosuke Yamazaki, Kazufumi Hisamatsu, Futoshi Akiyama, Seigo Nakamura; Japan Breast Cancer Research Group (JBCRG) |
| The 11th annual meeting of the Japanese Breast Cancer Society, Niigata, June 2003 |
